Genmab — August 2019

Plimsoller

God morgen

Helge_LarsenPI-redaktør

God morgen.

transalp

Go morgen...

E_L

World Lung conference https://www.evaluate.com/vantage/articles/events/conferences/world-lung-preview-astra-takes-roche

Plimsoller

@E L Does the link translate into that Bemcentinib + Keytruda is better than Enapotamab vedotin.

E_L

no, I don´t think that is what they are trying to imply, but it is clear that those are competition. It is still early days for EnaV; the data will have to prove its value. It is a good sign for now that it is being included in these conferences

Plimsoller

Ok. Thank you.

Bulder

Bergenbio's treatment is a combo. EnaV is mono and has not yet been tested in combination. Still too early to say. Maybe a comment from Sukker on this issue?

GeorgeBest

BerginBio is second line. EnaV is 4th plus lines. Therefore the EnaV patients are much more sick.

Bulder

Thx GB. I was not sure about that. Where did you find that info?

GeorgeBest

Bulder: can you read Nordea comments from 22 August?

Solsen

In the announcement they mentioned 4 lines or less

GeorgeBest

Nordea write: patients had failed 4 or more prior lines of therapy including platinum based chemo

Solsen

Makes a difference - perhaps Iam wrong

GeorgeBest

So infact EnaV is 5th line...

Solsen

who had failed ≤4 prior lines of therapy - right

Solsen

https://wclc2019.iaslc.org/wp-content/uploads/2019/08/WCLC2019-Abstract-Book_web-friendly.pdf pp 217-218

Solsen

Difficult comparison to Bergenbios compound.

Bulder

patients with stage III/IV
NSCLC without sensitizing EGFR mutations (EGFR WT) or ALK
rearrangements (ALK-
) who had failed ≤4 prior lines of therapy, så nogle har haft færre end 4 behandlinger.

Bulder

Bergenbio: Cohort A will consist of patients who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind. Cohort B will consist of patients with a maximum of 2 prior lines whereas the most recent line must have included a PD-(L)1 inhibitor.